Univercells S. A.

Univercells S. A.

Univercells is a global biomanufacturing innovator offering compact, low-cost end-to-end vaccine, virus, and biologics production platforms, accelerating access to affordable medicines.

Product

Belgium

Overview

Univercells, founded in 2013 and headquartered in Belgium, delivers groundbreaking end-to-end biomanufacturing solutions designed to make biologics, vaccines, and viral therapies more accessible and affordable worldwide.

Their innovative platforms—such as scale‑X single-use bioreactors, NevoLine™ upstream systems, Ntensify RNA production, and CDMO services—combine perfusion cell culture, integrated filtration, and continuous processing to slash manufacturing footprint, capital expenditures (up to 75%), and cost of goods (up to 90%) 

Univercells partners with global health leaders, biotech firms, and governments to deploy modular, scalable biologics capacity—including viral vector vaccines and gene therapies—in emerging and established markets. Backed by strategic investments from the Bill & Melinda Gates Foundation, Takeda Ventures, and acquired by Donaldson in 2023, Univercells continues to lead in compact, affordable, and sustainable bioproduction innovation

Contact Details

HQ Address

Avenue Centrale 52 Zoning de Jumet 6040 Charleroi, Belgium

Contact Person

Uday Ulhe
Email: u.ulhe@univercells.com

Landline: +32 2 318 83 48
Location: Belgium

  • Overview
  • Contact Details
Ad
Advertisement

Write a Review